Vise Technologies’s Tango Therapeutics TNGX Stock Holding History

Vise Technologies’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$319K	Buy	+12,802	New	+$333K	﹤0.01%	1656

Other funds holding TNGX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Mass General Brigham Somerville, Massachusetts $456M AUM 27.51% 1-Year Est. Return

Vise Technologies's TNGX Position: Q3 2026 in Review

Vise Technologies opened a new position in Tango Therapeutics (TNGX) in Q3 2026: 12,802 shares worth $319K. The stake represents ﹤0.01% of the portfolio and ranks #1656 among its holdings.

74 funds tracked by Wall St. Rank hold TNGX as of Q3 2026.

Vise Technologies held 12,802 shares of Tango Therapeutics worth $319K as of Q3 2026.
Tango Therapeutics was a new Vise Technologies position in Q3 2026.
Tango Therapeutics made up ﹤0.01% of Vise Technologies's portfolio in Q3 2026, its #1656 holding.
74 funds tracked by Wall St. Rank held Tango Therapeutics as of Q3 2026.

Based on Vise Technologies's 13F filing for Q3 2026, filed 29 Oct 2026.